S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:PROF

Profound Medical (PROF) Stock Price, News & Analysis

$8.20
-0.44 (-5.09%)
(As of 02/23/2024 ET)
Today's Range
$8.18
$8.50
50-Day Range
$7.30
$9.46
52-Week Range
$7.11
$15.49
Volume
52,860 shs
Average Volume
47,523 shs
Market Capitalization
$200.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.44

Profound Medical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
63.9% Upside
$13.44 Price Target
Short Interest
Bearish
1.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.04mentions of Profound Medical in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.24) to ($1.04) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.99 out of 5 stars

Medical Sector

776th out of 939 stocks

Surgical & Medical Instruments Industry

85th out of 93 stocks


PROF stock logo

About Profound Medical Stock (NASDAQ:PROF)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, palliative pain treatment of bone metastases, and osteoid osteoma. Profound Medical Corp. is headquartered in Mississauga, Canada.

PROF Stock Price History

PROF Stock News Headlines

Best way to buy gold today (not what you'd think)
With so many strange events happening across the economy (longest bear market for bonds since Civil War... unprecedented bank closures... and soaring prices) – it's no wonder the richest investors are loading up on gold. But what you might not realize is there's a much better way to profit from rising gold prices – without ever touching an ETF, mining stock, or even bullion.
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Profound Medical Corp.
Profound Medical Announces Non-Brokered Private Placement
See More Headlines
Receive PROF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/23/2024
Next Earnings (Confirmed)
3/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PROF
Employees
131
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.44
High Stock Price Target
$20.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+63.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-28,670,000.00
Net Margins
-452.72%
Pretax Margin
-447.96%

Debt

Sales & Book Value

Annual Sales
$6.68 million
Book Value
$2.49 per share

Miscellaneous

Free Float
24,058,000
Market Cap
$200.33 million
Optionable
Optionable
Beta
0.82
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Arun Swarup Menawat MBA (Age 69)
    Ph.D., Chairman of the Board & CEO
    Comp: $551.88k
  • Mr. Rashed Dewan (Age 56)
    Chief Financial Officer
    Comp: $250.37k
  • Mr. Hartmut Warnken (Age 51)
    Chief Commercial Officer of Outside US
    Comp: $224.93k
  • Dr. Mathieu Burtnyk (Age 42)
    Senior Vice President of Product Leader TULSA-PRO
    Comp: $246.1k
  • Mr. Abbey Goodman (Age 41)
    Chief Commercial Officer of US
    Comp: $353.75k
  • Mr. Stephen Kilmer
    Investor Relations
  • Mr. Jacques F. Cornet (Age 68)
    Senior VP & Product Leader Sonalleve
  • Mr. Matthew Sobczyk C.A.
    CPA, Assistant Corporate Controller
  • Mr. Levant Tinaz
    Software Developer














PROF Stock Analysis - Frequently Asked Questions

Should I buy or sell Profound Medical stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Profound Medical in the last year. There are currently 2 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PROF shares.
View PROF analyst ratings
or view top-rated stocks.

What is Profound Medical's stock price target for 2024?

4 analysts have issued 12 month price targets for Profound Medical's stock. Their PROF share price targets range from $10.00 to $20.00. On average, they expect the company's share price to reach $13.44 in the next year. This suggests a possible upside of 63.9% from the stock's current price.
View analysts price targets for PROF
or view top-rated stocks among Wall Street analysts.

How have PROF shares performed in 2024?

Profound Medical's stock was trading at $8.49 on January 1st, 2024. Since then, PROF stock has decreased by 3.4% and is now trading at $8.20.
View the best growth stocks for 2024 here
.

Are investors shorting Profound Medical?

Profound Medical saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 350,100 shares, an increase of 6.4% from the January 15th total of 329,100 shares. Based on an average daily trading volume, of 52,000 shares, the short-interest ratio is presently 6.7 days. Approximately 1.8% of the shares of the company are short sold.
View Profound Medical's Short Interest
.

When is Profound Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our PROF earnings forecast
.

How were Profound Medical's earnings last quarter?

Profound Medical Corp. (NASDAQ:PROF) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.03. The company had revenue of $2.54 million for the quarter, compared to the consensus estimate of $4 million. Profound Medical had a negative trailing twelve-month return on equity of 63.57% and a negative net margin of 452.72%. During the same quarter in the previous year, the business posted ($0.32) EPS.

What guidance has Profound Medical issued on next quarter's earnings?

Profound Medical issued an update on its fourth quarter 2023 earnings guidance on Wednesday, January, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.9 million-$2.0 million, compared to the consensus revenue estimate of $2.0 million.

Who are Profound Medical's major shareholders?

Profound Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Letko Brosseau & Associates Inc. (4.82%), AIGH Capital Management LLC (2.65%), Raymond James Financial Services Advisors Inc. (2.59%), Timelo Investment Management Inc. (2.50%), Royal Bank of Canada (1.64%) and Worth Venture Partners LLC (0.66%).

How do I buy shares of Profound Medical?

Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PROF) was last updated on 2/23/2024 by MarketBeat.com Staff